Published in Women's Health Weekly, May 12th, 2005
According to study author J.C. Gallagher and colleagues, "The relationship between prior fractures and risk of new fractures was evaluated in 931 postmenopausal women with prevalent vertebral fractures randomized to daily placebo or teriparatide (20 mcg) in the Fracture Prevention Trial. The median observation time was 21 months."
They reported, "Among placebo patients with 1, 2, or 3 or more prevalent vertebral fractures, 7, 16, and 23%,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly